Industry Briefs: August 20, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: August 20, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Antares Vision and Xyntek have formed a partnership for e-pedigree and serialization turnkey capabilities. Read More

Cambrex has agreed to supply an API for a customer’s Phase III program. The agreement is expected to contribute more than $20 million in revenues to Cambrex, which will expand its large-scale multipurpose cGMP assets in 2012 and 2013. Read More

Onyx Scientific and Molecular Profiles have formed an agreement to deliver end-to-end services from initial drug discovery to early- and late-phase manufacturing. Read More

Parker Hannifin has agreed to acquire SciLog, a provider of sensor technology and automated lab-scale and production systems for the biopharmaceutical industry.

FDA has approved Sanofi’s Auvi-Q (epinephrine injection), a voice-activated autoinjector for treating allergic reactions in people who are at risk for anaphylaxis. Read More

Sun Pharmaceutical has agreed to acquire Taro Pharmaceutical. Read More

TG Therapeutics and Rhizen Pharmaceutical have agreed to collaborate on the development and commercialization of Rhizen’s lead product candidate, a novel PI3K delta inhibitor, TGR-1202 (previously referred to as RP5264). Read More

People Notes

Avantor Performance Materials has named John M. Steitz president and CEO. Read More

ChanTest has appointed Chris Mathes as chief commercial officer. Read More

INC Research has named Jamie Macdonald CEO. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here